<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="topic" /><meta name="keywords" content="Pain: palliative care; Paracetamol: pain: palliative care; Analgesics: NSAIDs: palliative care; Metastron (strontium); Analgesics: opioid: palliative care; Codeine: pain: palliative care; Tramadol: pain: palliative care; Morphine: analgesia: palliative care; Hydromorphone: palliative care; Methadone: palliative care; Oxycodone: palliative care; Fentanyl: analgesia: palliative care; Diamorphine: morphine equivalence: intramuscular; Hydromorphone: morphine equivalence; Oxycodone: palliative care: morphine equivalence; Analgesics: opioid: equivalent doses; Morphine: analgesia: palliative care; Analgesics: NSAIDs: palliative care; Morphgesic SR: palliative care; MST Continus: palliative care; Zomorph: palliative care; MXL: palliative care; Pain: palliative care: breakthrough; Oxycodone: palliative care; Levomepromazine: palliative care; Diamorphine: pain: chronic; Morphine: analgesia: palliative care; Oxycodone: palliative care; Fentanyl: analgesia: palliative care; Buprenorphine: palliative care; Fentanyl: analgesia: morphine equivalence; Morphine: analgesia: fentanyl equivalence; Loperamide: palliative care; Hyoscine hydrobromide: palliative care: gastro-intestinal pain; Antacids: palliative care; Domperidone: palliative care; Gabapentin: neuropathic pain: palliative care; Pregabalin: neuropathic pain: palliative care; Ketamine: neuropathic pain: palliative care; Dexamethasone: neuropathic pain, palliative care" /><meta name="IX" content="Pain: palliative care; Paracetamol: pain: palliative care; Analgesics: NSAIDs: palliative care; Metastron (strontium); Analgesics: opioid: palliative care; Codeine: pain: palliative care; Tramadol: pain: palliative care; Morphine: analgesia: palliative care; Hydromorphone: palliative care; Methadone: palliative care; Oxycodone: palliative care; Fentanyl: analgesia: palliative care; Diamorphine: morphine equivalence: intramuscular; Hydromorphone: morphine equivalence; Oxycodone: palliative care: morphine equivalence; Analgesics: opioid: equivalent doses; Morphine: analgesia: palliative care; Analgesics: NSAIDs: palliative care; Morphgesic SR: palliative care; MST Continus: palliative care; Zomorph: palliative care; MXL: palliative care; Pain: palliative care: breakthrough; Oxycodone: palliative care; Levomepromazine: palliative care; Diamorphine: pain: chronic; Morphine: analgesia: palliative care; Oxycodone: palliative care; Fentanyl: analgesia: palliative care; Buprenorphine: palliative care; Fentanyl: analgesia: morphine equivalence; Morphine: analgesia: fentanyl equivalence; Loperamide: palliative care; Hyoscine hydrobromide: palliative care: gastro-intestinal pain; Antacids: palliative care; Domperidone: palliative care; Gabapentin: neuropathic pain: palliative care; Pregabalin: neuropathic pain: palliative care; Ketamine: neuropathic pain: palliative care; Dexamethasone: neuropathic pain, palliative care" /><title>Pain: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="29450.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="29450.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=29450.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="29403.htm">Guidance on prescribing</a> &gt; <a href="29446.htm">Prescribing in palliative care</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="29446.htm" title="Previous: Prescribing in palliative care">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="29458.htm" title="Next: Miscellaneous conditions">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_29450">Pain</h1><?highlighter on?><div id="pC" class="jN"><p><span>Analgesics</span> are more effective in preventing pain than in
the relief of established pain; it is important that they are given
regularly.</p><p><a title="monograph: PARACETAMOL" href="3469.htm#_3469"><b>Paracetamol</b></a> or a <b>NSAID</b> (<a title="sub-section: Non-steroidal anti-inflammatory drugs" href="5183.htm#_5183">section 10.1.1</a>) given
regularly will often make the use of opioid analgesics unnecessary.
A NSAID may also control the pain of <i>bone secondaries</i>; if necessary, <span>flurbiprofen</span> or <span>indometacin</span> can be given rectally. Radiotherapy, bisphosphonates (<a title=" Bisphosphonates" href="4446.htm#_4446">section 6.6.2</a>), and radioactive isotopes of <b>strontium</b> (<span class="cZ">Metastron</span>® available from GE Healthcare) may also
be useful for pain due to bone metastases.</p><p>An opioid analgesic (<a title="BNF:sub-section: Opioid analgesics" href="3491.htm#_3491">section 4.7.2</a>) such as <a title="BNF:monograph: CODEINE PHOSPHATE" href="3514.htm#_3514"><b>codeine</b></a>, alone or in combination with a non-opioid
analgesic at adequate dosage, may be helpful in the control of moderate
pain if non-opioid analgesics alone are not sufficient. Alternatively, <a title="BNF:monograph: TRAMADOL HYDROCHLORIDE" href="17872.htm#_17872"><b>tramadol</b></a> can be considered for moderate
pain. If these preparations do not control the pain, <a title="BNF:monograph: MORPHINE SALTS" href="3492.htm#_3492"><b><span>morphine</span></b></a> is the most useful opioid analgesic.
Alternatives to <span>morphine</span>, including <a title="BNF:monograph: HYDROMORPHONE HYDROCHLORIDE" href="65271.htm#_65271"><b>hydromorphone</b></a>, <a title="BNF:monograph: METHADONE HYDROCHLORIDE" href="3533.htm#_3533"><b>methadone</b></a>, <a title="BNF:monograph: OXYCODONE HYDROCHLORIDE" href="85406.htm#_85406"><b>oxycodone</b></a>, and transdermal <a title="BNF:monograph: FENTANYL" href="3530.htm#_3530"><b><span>fentanyl</span></b></a> (see below) are best initiated by those with experience
in palliative care. Initiation of an opioid analgesic should not be
delayed by concern over a theoretical likelihood of psychological
dependence (addiction).</p><div id="_207909"><div class="cBM" id="_tb0002">Equivalent single doses of opioid analgesics</div><table class="table" summary="Equivalent single doses of opioid analgesicsAnalgesics: opioid: equivalent doses" cellspacing="0" cellpadding="8" border="0" style="border-collapse: collapse;border-top: 1pt solid ; border-bottom: 1pt solid ; "><colgroup><col /><col /></colgroup><thead><tr><th style="border-bottom: 1pt solid ; " colspan="2">These equivalences are intended <b>only</b> as an approximate guide; patients should be carefully monitored after <b>any</b> change in medication and dose titration may be required</th></tr><tr><th style="border-bottom: 1pt solid ; ">Analgesic</th><th style="border-bottom: 1pt solid ; ">Dose</th></tr></thead><tbody><tr><td style="">Morphine salts (oral)</td><td style="">10 mg</td></tr><tr><td style="">Diamorphine hydrochloride (intramuscular)</td><td style="">3 mg</td></tr><tr><td style="">Hydromorphone hydrochloride</td><td style="">1.3 mg</td></tr><tr><td style="">Oxycodone (oral)</td><td style="">5 mg</td></tr></tbody></table></div><div class="cAZ" id="_201600"><h2>Oral route</h2> <p class="cAX"><a title="BNF:monograph: MORPHINE SALTS" href="3492.htm#_3492"><span>Morphine</span></a> is given <i>by mouth</i> as
an oral solution or as standard (‘immediate release’) tablets regularly
every 4 hours, the initial dose depending largely on the patient’s
previous treatment. A dose of 5–10 mg is enough to replace a weaker
analgesic (such as <span>paracetamol</span>), but 10–20 mg or
more is required to replace a strong one (comparable to <span>morphine</span> itself). If the first dose of <span>morphine</span> is no
more effective than the previous analgesic, the next dose should be
increased by 30–50%, the aim being to choose the lowest dose that
prevents pain. The dose should be adjusted with careful assessment
of the pain, and the use of adjuvant <span>analgesics</span> (such as NSAIDs) should also be considered. Although <span>morphine</span> in a dose of 5–20 mg is usually adequate there should be no hesitation
in increasing it stepwise according to response to 100 mg or occasionally
up to 500 mg or higher if necessary. It may be possible to omit the
overnight dose if double the usual dose is given at bedtime.</p><p>When the pain is controlled and the patient’s 24-hour <span>morphine</span> requirement is established, the daily dose can
be given as a <i>modified-release preparation</i> in a single
dose or in two divided doses.</p><p>Preparations suitable for twice-daily administration include <a title="BNF:preparation: Morphgesic® SR" href="128238.htm#_128238"><span class="cZ">Morphgesic</span>® <i>SR</i></a> tablets, <a title="BNF:preparation: MST Continus®" href="3499.htm#_3499"><span class="cZ">MST Continus</span>®</a> tablets or
suspension, and <a title="BNF:preparation: Zomorph®" href="65264.htm#_65264"><span class="cZ">Zomorph</span>®</a> capsules. <a title="BNF:preparation: MXL®" href="38995.htm#_38995"><span class="cZ">MXL</span>®</a> capsules allow administration of the total daily <span>morphine</span> requirement as a single dose.</p><p>The starting dose of modified-release morphine preparations
designed for twice daily administration is usually 10–20 mg every
12 hours if no other analgesic (or only <span>paracetamol</span>) has been taken previously, but to replace a weaker opioid analgesic
(such as co-codamol) the starting dose is usually 20–30 mg every 12
hours. Increments should be made to the dose, not to the frequency
of administration, which should remain at every 12 hours.</p><p>The effective dose of modified-release preparations can alternatively
be determined by giving the oral solution of <span>morphine</span> every 4 hours in increasing doses until the pain has been controlled,
and then transferring the patient to the same total 24-hour dose of <span>morphine</span> given as the modified-release preparation (divided
into two portions for 12-hourly administration). The first dose of
the modified-release preparation is given with, or within 4 hours
of, the last dose of the oral solution. The patient should be monitored
closely for treatment efficacy and side-effects.</p><p>If pain occurs between regular doses of morphine (‘breakthrough pain’),
an additional dose (‘rescue dose’) should be given. An additional
dose should also be given 30 minutes before an activity that causes
pain (e.g. wound dressing). <span>Morphine</span>, as oral solution
or standard formulation tablets, should be prescribed for breakthrough
pain. The standard dose of a strong opioid for breakthrough pain is
usually one-tenth to one-sixth of the regular 24 hour total daily
dose, repeated every 4 hours, or as necessary (review pain management
if analgesic required more frequently). Each patient should be assessed
on an individual basis. <span>Fentanyl</span> lozenges are also
licensed for breakthrough pain.</p><p><a title="monograph: OXYCODONE HYDROCHLORIDE" href="85406.htm#_85406"><b>Oxycodone</b></a> can be used in patients
who require an opioid but cannot tolerate morphine. If the patient
is already receiving an opioid, oxycodone should be started at a dose
equivalent to the current analgesic (see <a title="table: no context" href="29450.htm#_tb0002">Equivalent
Single Doses of Opioid Analgesics table</a>).</p> <p class="cAX"><a title="BNF:monograph: LEVOMEPROMAZINE" href="3231.htm#_3231"><b>Levomepromazine</b></a> is licensed to treat pain in palliative
care. However, such use is reserved for distressed patients with severe
pain unresponsive to other measures (seek specialist advice).</p></div><div class="cAZ"><h2>Parenteral route</h2> <p class="cAX">If the patient becomes unable
to swallow, the equivalent intramuscular dose of <span>morphine</span> is half the oral solution dose; in the case of the modified-release
tablets it is half the total 24-hour dose (which is then divided into
6 portions to be given every 4 hours). <a title="BNF:monograph: DIAMORPHINE HYDROCHLORIDE" href="3521.htm#_3521"><b>Diamorphine </b></a>  is preferred for injection
because, being more soluble, it can be given in a smaller volume.
The equivalent intramuscular (or subcutaneous) dose is approximately
a third of the oral dose of <span>morphine</span>. <i>Subcutaneous
infusion</i> of diamorphine via continuous infusion device can
be useful (for details, see <a title="topic: Syringe drivers" href="29476.htm#_29476">Continuous Infusion Devices</a>).</p><p>If the patient can resume taking medicines by mouth, then oral <span>morphine</span> may be substituted for subcutaneous infusion of
diamorphine. See <a title="target-block: Equivalent doses of morphine sulphate" href="29476.htm#_120035">table</a> of approximate
equivalent doses of morphine and diamorphine. </p></div><div class="cAZ"><h2>Rectal route</h2> <p class="cAX"><a title="BNF:preparation: Morphine" href="9664.htm#_9664"><b>Morphine</b></a> is also available for <i>rectal
administration</i> as suppositories; alternatively <a title="BNF:monograph: OXYCODONE HYDROCHLORIDE" href="85406.htm#_85406"><b>oxycodone</b></a> suppositories can be obtained
on special order.</p></div><div id="_120544"><div class="cAZ"><h2>Transdermal route</h2> <p class="cAX">Transdermal preparations of <span>fentanyl</span> and buprenorphine are available (<a title=" Opioid analgesics" href="3491.htm#_3491">section 4.7.2</a>); they are not suitable for acute pain or in
patients whose analgesic requirements are changing rapidly because
the long time to steady state prevents rapid titration of the dose.
Prescribers should ensure that they are familiar with the correct
use of transdermal preparations (see under <a title="BNF:monograph: FENTANYL" href="3530.htm#_3530">Fentanyl</a>) because inappropriate use has caused
fatalities.</p><p>The following 24-hour doses of <span>morphine</span> <b>by mouth</b> are considered to be approximately equivalent to
the <span>fentanyl</span> patches shown:</p><ul class="cBD"><li><p class="cQ"><span>Morphine</span> salt 45 mg daily ≡ <span>fentanyl</span> ‘12’ patch</p></li><li><p class="cQ"><span>Morphine</span> salt 90 mg daily ≡ <span>fentanyl</span> ‘25’ patch</p></li><li><p class="cQ"><span>Morphine</span> salt 180 mg daily ≡ <span>fentanyl</span> ‘50’ patch</p></li><li><p class="cQ"><span>Morphine</span> salt 270 mg daily ≡ <span>fentanyl</span> ‘75’ patch</p></li><li><p class="cQ"><span>Morphine</span> salt 360 mg daily ≡ <span>fentanyl</span> ‘100’ patch</p></li></ul><p><span>Morphine</span> (as oral solution or standard formulation
tablets) is given for breakthrough pain.</p></div></div><div class="cAZ"><h2>Gastro-intestinal pain</h2> <p class="cAX">The pain of <i>bowel
colic</i> may be reduced by loperamide 2–4 mg 4 times daily. Hyoscine hydrobromide (<a title="monograph: HYOSCINE HYDROBROMIDE" href="3451.htm#_3451">section 4.6</a>) may also be helpful, given sublingually
at a dose of 300 micrograms 3 times daily as <span class="cZ">Kwells</span>® tablets. Subcutaneous injections of hyoscine butylbromide, hyoscine
hydrobromide, and glycopyrronium can also be used to treat bowel colic
(see below). For doses by subcutaneous infusion, see <a title="target-block: BOWEL COLIC AND EXCESSIVE RESPIRATORY SECRETIONS" href="29476.htm#_120046">Bowel Colic and Excessive
Respiratory Secretions</a>).</p><p>Gastric distension pain due to pressure on the stomach may be
helped by a preparation incorporating an antacid with an antiflatulent (<a title="target-text: Dimeticone for flatulence and hiccup" href="2017.htm#_2017.3">section 1.1.1</a>) and
a prokinetic such as <span>domperidone</span> 10 mg 3 times daily
before meals.</p></div><div class="cAZ"><h2>Muscle spasm</h2> <p class="cAX">The pain of muscle spasm can be helped
by a muscle relaxant such as <span>diazepam</span> 5–10 mg daily
or <span>baclofen</span> 5–10 mg 3 times daily.</p></div><div id="_120545"><div class="cAZ"><h2>Neuropathic pain</h2> <p class="cAX">Patients with neuropathic pain
(<a title="sub-section: Neuropathic pain" href="3548.htm#_3548">section 4.7.3</a>) may benefit from a trial of
a tricyclic antidepressant for several weeks. An anticonvulsant may
be added or substituted if pain persists; <span>gabapentin</span> and <span>pregabalin</span> (both <a title="monograph-family: Gabapentin" href="89413.htm#_89413">section 4.8.1</a>) are licensed for neuropathic
pain. Ketamine is sometimes used under specialist supervision for neuropathic
pain that responds poorly to opioid analgesics.</p><p>Pain due to nerve compression may be reduced by a corticosteroid
such as <span>dexamethasone</span> 8 mg daily, which reduces oedema
around the tumour, thus reducing compression.</p><p><b>Nerve blocks</b> or regional anaesthesia techniques
(including the use of epidural and intrathecal catheters) can be considered
when pain is localised to a specific area.</p></div></div></div><?highlighter on?><?highlighter off?><div id="pE">◄ <a accesskey="[" href="29446.htm">Previous: Prescribing in palliative care</a> | <a class="top" href="29450.htm#">Top</a> | <a accesskey="]" href="29458.htm">Next: Miscellaneous conditions</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>